Literature DB >> 22833540

Pulmonary metastasectomy for osteogenic and soft tissue sarcoma: who really benefits from surgical treatment?

Tetsuya Mizuno1, Tetsuo Taniguchi, Yoshinori Ishikawa, Koji Kawaguchi, Takayuki Fukui, Futoshi Ishiguro, Shota Nakamura, Kohei Yokoi.   

Abstract

OBJECTIVES: Surgical resection is widely accepted as a beneficial treatment of pulmonary metastases originating from osteogenic and soft tissue sarcomas despite adequate validation. The factors associated with the selection of patients who receive pulmonary metastasectomy (PM) are controversial and not well known. In this study, we aimed to identify the prognostic factors associated with survival after treatment with PM and to disclose the candidates who profit from PM being performed on patients with osteogenic and soft tissue sarcomas.
METHODS: We retrospectively reviewed the variables and survival outcomes in 52 consecutive patients who underwent PM to treat lung metastases originating from osteogenic and soft tissue malignancies from April 1996 to January 2011. Prognostic factors associated with overall survival after the first PM were evaluated using univariate and multivariate analyses.
RESULTS: Fifty-eight PM procedures were performed in 52 patients as the first PM including 6 bilateral diseases. Wedge resection was the most frequently performed PM procedure (84%), and video-assisted thoracic surgery was introduced in 34 (59%). The median follow-up of the patients was 33 months and the 5-year survival rate after the first PM was 50.9%. Forty-eight (92%) patients underwent complete resection during the first PM. Thirty-three patients (62%) experienced relapse after the first PM. Among those patients, 20 received redo surgeries for pulmonary relapse, and the 5-year survival rate in this group was 49.7%. According to univariate analyses, the use of complete resection, the number of metastatic nodules (one or two) and the length of the disease-free interval prior to the first PM were each found to be significant favourable factors. According to a multivariate analysis, the use of complete resection and the number of metastatic nodules were both found to be independent prognostic factors associated with overall survival. Although our cohort included 15 patients with poor prognostic factors (29%), 5 patients who underwent redo surgery survived >22 months.
CONCLUSIONS: The survival of those patients with one or two pulmonary nodules and those who underwent complete resection was favourable following the treatment of osteogenic and soft tissue sarcomas with PM. Redo surgery may also provide some survival benefit in patients with poor prognostic factors.

Entities:  

Mesh:

Year:  2012        PMID: 22833540     DOI: 10.1093/ejcts/ezs419

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  13 in total

Review 1.  Pulmonary metastasectomy: outcomes and issues according to the type of surgical resection.

Authors:  Masahiko Higashiyama; Toshiteru Tokunaga; Tomoyuki Nakagiri; Daisuke Ishida; Hidenori Kuno; Jiro Okami
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-04-03

Review 2.  Management of Sarcoma Metastases to the Lung.

Authors:  Christopher S Digesu; Ory Wiesel; Ara A Vaporciyan; Yolonda L Colson
Journal:  Surg Oncol Clin N Am       Date:  2016-10       Impact factor: 3.495

3.  Prognostic influence of the treatment approach for pulmonary metastasis in patients with soft tissue sarcoma.

Authors:  Teruya Kawamoto; Hitomi Hara; Masayuki Morishita; Naomasa Fukase; Yohei Kawakami; Toshiyuki Takemori; Shuichi Fujiwara; Kazumichi Kitayama; Shunsuke Yahiro; Tomohiro Miyamoto; Takuya Fujimoto; Ikuo Fujita; Kenichiro Kakutani; Tomoyuki Matsumoto; Takehiko Matsushita; Takahiro Niikura; Ryosuke Kuroda; Toshihiro Akisue
Journal:  Clin Exp Metastasis       Date:  2020-05-20       Impact factor: 5.150

4.  Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma.

Authors:  Neel P Chudgar; Murray F Brennan; Rodrigo R Munhoz; Peter R Bucciarelli; Kay See Tan; Sandra P D'Angelo; Manjit S Bains; Matthew Bott; James Huang; Bernard J Park; Valerie W Rusch; Prasad S Adusumilli; William D Tap; Samuel Singer; David R Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2017-03-21       Impact factor: 5.209

Review 5.  Survival and prognostic factors following pulmonary metastasectomy for sarcoma.

Authors:  Giuseppe Marulli; Marco Mammana; Giovanni Comacchio; Federico Rea
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

6.  Cardiovascular involvement by osteosarcoma: an analysis of 20 patients.

Authors:  Sireesha Yedururi; Ajaykumar C Morani; Gregory W Gladish; Srilakshmi Vallabhaneni; Peter M Anderson; Dennis Hughes; Wei-Lien Wang; Najat C Daw
Journal:  Pediatr Radiol       Date:  2015-09-28

7.  Pulmonary metastasectomy for sarcoma-survival and prognostic analysis.

Authors:  Wojciech Dudek; Waldemar Schreiner; Iurii Mykoliuk; Mostafa Higaze; Horia Sirbu
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

8.  Pulmonary metastasectomy in sarcoma-experiences with laser-assisted resection.

Authors:  Severin Schmid; Uyen-Thao Le; Christoph Zeisel; Benedikt Haager; Bernward Passlick
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

9.  Survival prognostic and recurrence risk factors after single pulmonary metastasectomy.

Authors:  Céline Forster; Amaya Ojanguren; Jean Yannis Perentes; Matthieu Zellweger; Thorsten Krueger; Etienne Abdelnour-Berchtold; Michel Gonzalez
Journal:  J Cardiothorac Surg       Date:  2021-12-28       Impact factor: 1.637

10.  Evaluation of intraarterial and intravenous cisplatin chemotherapy in the treatment of metastatic osteosarcoma using an orthotopic xenograft mouse model.

Authors:  Bernhard Robl; Sander Martijn Botter; Giovanni Pellegrini; Olga Neklyudova; Bruno Fuchs
Journal:  J Exp Clin Cancer Res       Date:  2016-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.